BR9710156A - Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia - Google Patents

Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Info

Publication number
BR9710156A
BR9710156A BR9710156A BR9710156A BR9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A
Authority
BR
Brazil
Prior art keywords
treat
patient suffering
hypertension
reduce
levels
Prior art date
Application number
BR9710156A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael R Myers
Martin P Maguire
Alfred P Spada
William R Ewing
Henry W Pauls
Yong-Mi Choi-Sledeski
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9710156A publication Critical patent/BR9710156A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9710156A 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia BR9710156A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2136696P 1996-07-08 1996-07-08
PCT/US1997/011320 WO1998001426A1 (en) 1996-07-08 1997-07-01 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

Publications (1)

Publication Number Publication Date
BR9710156A true BR9710156A (pt) 1999-08-10

Family

ID=21803790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710156A BR9710156A (pt) 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Country Status (22)

Country Link
EP (1) EP0912520B1 (enExample)
JP (1) JP4202421B2 (enExample)
KR (1) KR20000023635A (enExample)
CN (1) CN1228770A (enExample)
AP (1) AP903A (enExample)
AT (1) ATE239725T1 (enExample)
AU (1) AU746590B2 (enExample)
BG (1) BG103135A (enExample)
BR (1) BR9710156A (enExample)
CA (1) CA2259538C (enExample)
CZ (1) CZ291785B6 (enExample)
DE (1) DE69721776T2 (enExample)
EA (1) EA001801B1 (enExample)
ES (1) ES2199365T3 (enExample)
HU (1) HUP9903815A3 (enExample)
IL (1) IL127890A0 (enExample)
NO (1) NO313671B1 (enExample)
OA (1) OA10953A (enExample)
PL (1) PL331036A1 (enExample)
SK (1) SK2299A3 (enExample)
UA (1) UA51716C2 (enExample)
WO (1) WO1998001426A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
JP3933870B2 (ja) 1998-06-23 2007-06-20 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU1186300A (en) 1998-11-25 2000-06-13 Daiichi Radioisotope Laboratories, Ltd. Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient
PT1140933E (pt) * 1998-12-31 2004-12-31 Aventis Pharma Inc Processo para preparar derivados n6-substituidos de desaza-adenosina
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1392690A2 (en) * 2001-05-10 2004-03-03 Aventis Pharma Deutschland GmbH Novel processes for the preparation of adenosine compounds and intermediates thereto
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
EP1574508A1 (de) 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
JP2006022045A (ja) * 2004-07-08 2006-01-26 Kaneka Corp 光学活性１−ｔ−ブトキシカルボニル−３−アミノピロリジン塩の単離精製方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
HK1254892A1 (zh) * 2016-01-14 2019-08-02 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途
CN110627765B (zh) * 2019-10-14 2021-08-20 浙江乐普药业股份有限公司 一种替卡格雷关键中间体的制备方法
CN112047919B (zh) * 2020-09-16 2021-06-18 常州制药厂有限公司 一种替卡格雷中间体及其制备方法
KR102308854B1 (ko) * 2021-02-26 2021-10-05 퓨쳐메디신 주식회사 카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1995018817A1 (fr) * 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids

Also Published As

Publication number Publication date
AP9801426A0 (en) 1998-12-31
EP0912520A4 (en) 1999-10-06
EA199900092A1 (ru) 1999-08-26
EA001801B1 (ru) 2001-08-27
SK2299A3 (en) 2000-10-09
EP0912520A1 (en) 1999-05-06
KR20000023635A (ko) 2000-04-25
WO1998001426A1 (en) 1998-01-15
PL331036A1 (en) 1999-06-21
ES2199365T3 (es) 2004-02-16
NO990063L (no) 1999-03-08
AP903A (en) 2000-11-24
ATE239725T1 (de) 2003-05-15
CZ2499A3 (cs) 1999-05-12
HUP9903815A3 (en) 2002-04-29
CA2259538C (en) 2006-12-19
CA2259538A1 (en) 1998-01-15
NO990063D0 (no) 1999-01-07
OA10953A (en) 2001-10-26
BG103135A (bg) 1999-11-30
EP0912520B1 (en) 2003-05-07
NO313671B1 (no) 2002-11-11
UA51716C2 (uk) 2002-12-16
IL127890A0 (en) 1999-10-28
DE69721776D1 (de) 2003-06-12
HUP9903815A1 (hu) 2001-04-28
JP2000514801A (ja) 2000-11-07
JP4202421B2 (ja) 2008-12-24
AU746590B2 (en) 2002-05-02
CN1228770A (zh) 1999-09-15
AU3645497A (en) 1998-02-02
CZ291785B6 (cs) 2003-05-14
DE69721776T2 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
BR9710156A (pt) Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia
BR9507327A (pt) Composto composições para tratar uma donça cardiovascular marcada por hipertensão ou hipertensão ou isquemia do miocárdio melhorar os danos isquémicos ou reduzir o tamanho do infarto do miocárdio e reduzir niveis de lipideos triglicerideos ou de colesterol em um mamifero e processos para tratar um paciente que sofre de hipertensão de isquemia do miocárdio e de hiperlipidemia ou hipercolesterolina para melhorar em um paciente danos isquémicos ou o tamanho do infarto do miocádio e para preparar um derivado substancialmente opticamente puro de 2 substituido-2-amido-1-(heteroar-2-3-il) etano
CO4970694A1 (es) Amlodipino y atorvastatina utiles en el tratamiento de angina de pecho, ateroesclerosis, hipertension e hiperlipidemia
PT1023891E (pt) Composicao anidra de descoloracao das fibras queratinicas compreendendo a associacao de polimeros anfifilicos anionicos e/ou nao ionicos compreendendo pelo menos uma cadeia gorda e de polimeros substantivos cationicos ou anfotericos
MA24391A1 (fr) Progesterone pour traiter ou reduire l'ischemie
FR16C0008I2 (fr) Utilisation combinee de valsartane et bloqueurs du canal de calcium a but therapeutique
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
BR9508586A (pt) Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica
EP0963200A4 (en) METHOD AND MEANS FOR INHIBITING ANGIOGENESIS
CY2010002I1 (el) Στepεη φαρμακευτικη συνθεση πepιεχοντας παραγωγα βενζοφουρανιου
CA2375225A1 (en) Mutual salt of amlodipine and atorvastatin
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
FI953915L (fi) Dupuytrenin taudin lievittämiseen
EP0946178A4 (en) COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
ID26029A (id) Komposisi untuk mengurangi berat
BR0011006A (pt) Prõ-drogas mútuas de amlodipina e atorvastatina
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
BR0313209A (pt) proteìnas que interagem com mk2
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
DK0710315T3 (da) Forskallingsplade med drager med omtrentligt U-formet tværsnit
DZ2654A1 (fr) Utilisations des kétolides pour la préparation de compositions pharmaceutiques destinées à prévenir les complications thrombotiques artérielles liées à l'arthérosclérose.
NO983526D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
ES2173663T3 (es) Composicion adsorbente.
SE9603668D0 (sv) Pharmaceutical compositions
BR9915700A (pt) Estrutura feita de elementos de alma para treliças, e, treliça

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.